Among secondary outcomes, GLP-1 RA Users exhibited a higher risk of acute pancreatitis (HR 1.519, 95% CI 1.473–1.568), chronic pancreatitis (HR 1.464, 95% CI 1.387–1.546), and pancreatic cancer (HR 1.210, 95% CI 1.140–1.284), compared to Non–GLP-1 RA Users (Table 2). Here, GLP1R is linked to pancreatic neoplasm.